ASCO: AstraZeneca wants to challenge rivals for immunotherapy class
This article was originally published in Scrip
Executive Summary
There was no cutting-edge data from AstraZeneca or its biotech business MedImmune at this year’s ASCO, the big annual US cancer research meeting. That was made clear in advance of the Chicago conference. (scripintelligence.com May 16, 2013)